Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 1/2 1

Status

Completed 14Terminated 3Unknown 2Withdrawn 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 6Other solid neoplasm 2Head & Neck 2Gynecologic 2Sarcoma 1Breast 1

Conditions

Ovarian Neoplasms 2Thyroid Neoplasms 1Endometrial Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

Paclitaxel 79Cisplatin 72Carboplatin 72Bevacizumab 29Radiotherapy 27Brachytherapy 23Hyperthermic Intraperitoneal Chemotherapy 20Drug Therapy 20olaparib 19Gemcitabine 17niraparib 16apatinib 16pembrolizumab 15Surgical Procedures, Operative 15liposomal doxorubicin 12Cyclophosphamide 12Surveys and Questionnaires 11camrelizumab 10Taxes 10Neoadjuvant Therapy 10fludarabine 9anlotinib 9Etoposide 9Blood Specimen Collection 9Topotecan 8Docetaxel 8Sentinel Lymph Node Biopsy 7Platinum 7Injections 7Cytoreduction Surgical Procedures 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × pazopanib × Gynecologic × Clear all
NCT05949424 2023-11-29

OPTI-DOSE

University Medical Center Groningen

Phase 4 Unknown
30 enrolled
BreastGenitourinaryGynecologicHead & Neck

Breast Neoplasms, Carcinoma, Renal Cell, Ovarian Neoplasms, Thyroid Neoplasms, Endometrial Neoplasms

NCT01600573 2016-10-11

Pazopanib and Weekly Topotecan in Patients Recurrent Ovarian Cancer (TOPAZ)

Charite University, Berlin, Germany

Phase 1/2 Unknown
68 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡